438 related articles for article (PubMed ID: 22394614)
1. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
Blagosklonny MV
Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin, proliferation and geroconversion to senescence.
Blagosklonny MV
Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
[TBL] [Abstract][Full Text] [Related]
3. MEK drives cyclin D1 hyperelevation during geroconversion.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
[TBL] [Abstract][Full Text] [Related]
4. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
Leontieva OV; Blagosklonny MV
Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin and the inhibition of the secretory phenotype.
Wang R; Sunchu B; Perez VI
Exp Gerontol; 2017 Aug; 94():89-92. PubMed ID: 28167236
[TBL] [Abstract][Full Text] [Related]
6. Cellular senescence: when growth stimulation meets cell cycle arrest.
Blagosklonny MV
Aging (Albany NY); 2023 Feb; 15(4):905-913. PubMed ID: 36805938
[TBL] [Abstract][Full Text] [Related]
7. Cell senescence, rapamycin and hyperfunction theory of aging.
Blagosklonny MV
Cell Cycle; 2022 Jul; 21(14):1456-1467. PubMed ID: 35358003
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
[TBL] [Abstract][Full Text] [Related]
9. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
[TBL] [Abstract][Full Text] [Related]
10. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
Leontieva OV; Blagosklonny MV
Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
[TBL] [Abstract][Full Text] [Related]
11. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
Leontieva OV; Demidenko ZN; Blagosklonny MV
Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
[TBL] [Abstract][Full Text] [Related]
12. Geroconversion: irreversible step to cellular senescence.
Blagosklonny MV
Cell Cycle; 2014; 13(23):3628-35. PubMed ID: 25483060
[TBL] [Abstract][Full Text] [Related]
13. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.
Blagosklonny MV
Cell Cycle; 2011 Jul; 10(14):2295-8. PubMed ID: 21715978
[TBL] [Abstract][Full Text] [Related]
14. mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.
Wesierska-Gadek J
Aging (Albany NY); 2010 Dec; 2(12):892-3. PubMed ID: 21149896
[No Abstract] [Full Text] [Related]
15. Paradoxical suppression of cellular senescence by p53.
Demidenko ZN; Korotchkina LG; Gudkov AV; Blagosklonny MV
Proc Natl Acad Sci U S A; 2010 May; 107(21):9660-4. PubMed ID: 20457898
[TBL] [Abstract][Full Text] [Related]
16. S6K in geroconversion.
Leontieva OV; Demidenko ZN; Blagosklonny MV
Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
[TBL] [Abstract][Full Text] [Related]
17. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
18. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.
Leontieva OV; Lenzo F; Demidenko ZN; Blagosklonny MV
Cell Cycle; 2012 Dec; 11(24):4642-9. PubMed ID: 23187803
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia and gerosuppression: the mTOR saga continues.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2012 Nov; 11(21):3926-31. PubMed ID: 22987149
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
